Covered recipient · General Payments record
SCOTT T GUENTHNER
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$57,960.84
183 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,921.00 | 17 |
| Honoraria | $9,800.00 | 4 |
| Consulting Fee | $6,575.00 | 6 |
| Travel and Lodging | $2,908.23 | 6 |
| Food and Beverage | $2,684.66 | 148 |
| Education | $71.95 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Scientific Affairs, LLC | $24,140.31 | 19 |
| AbbVie Inc. | $10,208.89 | 34 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $10,014.35 | 19 |
| Lilly USA, LLC | $2,887.57 | 9 |
| Novartis Pharmaceuticals Corporation | $2,689.23 | 40 |
| Senseonics, Incorporated | $2,120.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $1,703.09 | 2 |
| Janssen Biotech, Inc. | $1,636.43 | 25 |
| ParaPRO, LLC | $1,000.00 | 1 |
| Almirall LLC | $822.62 | 2 |
| UCB, Inc. | $213.23 | 6 |
| STRATA Skin Sciences, Inc. | $159.98 | 2 |
| VYNE Pharmaceuticals Inc. | $71.33 | 4 |
| PFIZER INC. | $63.66 | 5 |
| Galderma Laboratories, L.P. | $37.60 | 3 |
| GENZYME CORPORATION | $31.95 | 2 |
| DERMIRA, INC. | $30.94 | 1 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $26.83 | 2 |
| LEO Pharma Inc. | $26.57 | 2 |
| Midmark Corporation | $26.48 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.22 | 1 |
| EPI Health, LLC | $17.27 | 1 |
| MAYNE PHARMA INC. | $13.29 | 1 |
Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SCOTT T GUENTHNER
NPI 1396748778 · CMS profile ID 154244
Allopathic & Osteopathic Physicians / Dermatology
PLAINFIELD, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1396748778?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SCOTT T GUENTHNER, NPI 1396748778, CMS profile ID 154244. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396748778?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). SCOTT T GUENTHNER, NPI 1396748778, CMS profile ID 154244. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396748778?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- SCOTT T GUENTHNER, NPI 1396748778, CMS profile ID 154244, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1396748778?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
183 matching records · $57,960.84 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 183.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $13.08 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192835 | CMS |
| PFIZER INC. | $12.88 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832531329 | CMS |
| Novartis Pharmaceuticals Corporation | $6.43 | 06/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703141 | CMS |
| AbbVie Inc. | $18.26 | 06/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687331 | CMS |
| AbbVie Inc. | $2,100.00 | 06/14/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687327 | CMS |
| UCB, Inc. | $10.12 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807356821 | CMS |
| AbbVie Inc. | $14.71 | 06/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687323 | CMS |
| Novartis Pharmaceuticals Corporation | $2.90 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703139 | CMS |
| STRATA Skin Sciences, Inc. | $120.00 | 06/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852389699 | CMS |
| LEO Pharma Inc. | $14.47 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 842198809 | CMS |
| Novartis Pharmaceuticals Corporation | $9.99 | 06/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703135 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $1,600.00 | 06/02/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851928641 | CMS |
| Galderma Laboratories, L.P. | $11.85 | 06/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855277897 | CMS |
| Janssen Scientific Affairs, LLC | $1,350.00 | 05/29/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192869 | CMS |
| PFIZER INC. | $14.49 | 05/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832526561 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $15.38 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849566537 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $14.55 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851928589 | CMS |
| AbbVie Inc. | $19.87 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687319 | CMS |
| Lilly USA, LLC | $15.55 | 05/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818743513 | CMS |
| AbbVie Inc. | $2,100.00 | 05/17/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687315 | CMS |
| Novartis Pharmaceuticals Corporation | $2.28 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703137 | CMS |
| Novartis Pharmaceuticals Corporation | $12.14 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703129 | CMS |
| AbbVie Inc. | $7.68 | 05/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687311 | CMS |
| Novartis Pharmaceuticals Corporation | $2.32 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703127 | CMS |
| AbbVie Inc. | $14.72 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687307 | CMS |
| Novartis Pharmaceuticals Corporation | $3.14 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703133 | CMS |
| Almirall LLC | $22.62 | 05/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819691205 | CMS |
| Janssen Biotech, Inc. | $16.91 | 05/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192825 | CMS |
| Janssen Scientific Affairs, LLC | $15.12 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192901 | CMS |
| Novartis Pharmaceuticals Corporation | $0.71 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703125 | CMS |
| AbbVie Inc. | $16.80 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687303 | CMS |
| Janssen Biotech, Inc. | $1.89 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192831 | CMS |
| Lilly USA, LLC | $1,400.00 | 04/28/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818697873 | CMS |
| AbbVie Inc. | $18.53 | 04/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687299 | CMS |
| Janssen Scientific Affairs, LLC | $1,350.00 | 04/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192867 | CMS |
| AbbVie Inc. | $8.16 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687295 | CMS |
| Janssen Biotech, Inc. | $15.30 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788192841 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $29.69 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851928605 | CMS |
| Senseonics, Incorporated | $2,120.00 | 04/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855254899 | CMS |
| Novartis Pharmaceuticals Corporation | $3.77 | 04/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703123 | CMS |
| Novartis Pharmaceuticals Corporation | $5.14 | 04/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703131 | CMS |
| Galderma Laboratories, L.P. | $11.62 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855277895 | CMS |
| AbbVie Inc. | $17.39 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687291 | CMS |
| Novartis Pharmaceuticals Corporation | $1.37 | 04/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703115 | CMS |
| AbbVie Inc. | $2,100.00 | 04/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794687287 | CMS |
| Lilly USA, LLC | $12.42 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818750327 | CMS |
| Novartis Pharmaceuticals Corporation | $1.62 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703121 | CMS |
| UCB, Inc. | $130.00 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 807323577 | CMS |
| Novartis Pharmaceuticals Corporation | $7.35 | 03/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812703119 | CMS |
| Almirall LLC | $800.00 | 03/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 819687563 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,201,070.78 | 147 |
| PY2024 | Recipient | $104.58 | 1 |
| PY2024 | Principal investigator | $1,501,958.86 | 619 |
| PY2023 | Recipient | $5,500.00 | 1 |
| PY2023 | Principal investigator | $1,258,025.01 | 629 |
| PY2022 | Recipient | $3,236.49 | 3 |
| PY2022 | Principal investigator | $990,155.85 | 312 |
| PY2021 | Recipient | $26,862.89 | 2 |
| PY2021 | Principal investigator | $1,423,829.74 | 155 |
| PY2020 | Recipient | $19,508.34 | 16 |
| PY2020 | Principal investigator | $1,057,824.31 | 213 |
| PY2019 | Recipient | $72,878.15 | 31 |
| PY2019 | Principal investigator | $1,578,189.19 | 248 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
147 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $485.00 | 12/24/2025 | Non-covered Recipient Entity The Indiana Clinical Trials Center | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | No dispute reported | 06/30/2026 | 1226105802 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $600.00 | 12/24/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435235 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,226.00 | 12/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175333614 |
| Principal investigator 1 | Incyte Corporation | $3,148.00 | 12/19/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602165 |
| Principal investigator 1 | Incyte Corporation | $2,027.00 | 12/19/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602174 |
| Principal investigator 1 | Incyte Corporation | $1,890.00 | 12/19/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602193 |
| Principal investigator 1 | Incyte Corporation | $2,131.00 | 12/19/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602212 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,558.00 | 12/19/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333885 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 12/18/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602182 |
| Principal investigator 1 | Incyte Corporation | $544.00 | 12/18/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602189 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,078.26 | 12/18/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435145 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,246.75 | 12/12/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435232 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 12/11/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333803 |
| Principal investigator 1 | ABBVIE INC. | $9,200.00 | 12/10/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202529924 |
| Principal investigator 1 | Janssen Research & Development, LLC | $420.00 | 12/08/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175333713 |
| Principal investigator 1 | Biofrontera Inc. | $4,759.13 | 12/05/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907785 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,324.25 | 12/04/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435213 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,801.90 | 12/04/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435217 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,088.47 | 12/04/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435221 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,231.65 | 12/04/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435225 |
| Principal investigator 1 | Incyte Corporation | $7,500.00 | 12/01/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602170 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,970.00 | 12/01/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175333770 |
| Principal investigator 1 | Biofrontera Inc. | $16,701.00 | 11/28/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907764 |
| Principal investigator 1 | Biofrontera Inc. | $341.14 | 11/28/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907769 |
| Principal investigator 1 | Biofrontera Inc. | $47,343.61 | 11/28/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907772 |
| Principal investigator 1 | Biofrontera Inc. | $1,173.00 | 11/28/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907776 |
| Principal investigator 1 | Incyte Corporation | $1,834.00 | 11/21/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602196 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 11/14/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602167 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 11/14/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602178 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 11/14/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602201 |
| Principal investigator 1 | Incyte Corporation | $8,500.00 | 11/14/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602216 |
| Principal investigator 1 | Janssen Research & Development, LLC | $215.00 | 11/14/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219400 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $7,631.54 | 11/13/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435138 |
| Principal investigator 1 | Janssen Research & Development, LLC | $212.00 | 11/10/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175333699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 11/10/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175333782 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,200.00 | 11/10/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175333837 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,434.88 | 11/05/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435208 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $5,400.00 | 11/05/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232946825 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 11/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602161 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 11/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602222 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,558.00 | 10/31/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333524 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,605.00 | 10/31/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175333570 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 10/23/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $311.00 | 10/23/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219409 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $11,806.42 | 10/23/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435122 |
| Principal investigator 1 | Incyte Corporation | $2,131.00 | 10/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602157 |
| Principal investigator 1 | Incyte Corporation | $3,148.00 | 10/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602185 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $200.00 | 10/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232946610 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,350.00 | 10/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232946614 |
| Principal investigator 1 | Eli Lilly and Company | $15,344.00 | 10/14/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187891212 |
| Principal investigator 1 | Incyte Corporation | $544.00 | 10/13/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602205 |
| Principal investigator 1 | Incyte Corporation | $10.00 | 10/13/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTRE, PC | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240602209 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,404.35 | 10/10/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435205 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 10/09/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333867 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,712.35 | 10/09/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435112 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,302.00 | 09/29/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333563 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,710.00 | 09/29/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333992 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,316.00 | 09/29/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175334158 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,634.95 | 09/25/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,532.00 | 09/08/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333674 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,710.00 | 09/08/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333743 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 09/08/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175334060 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,651.00 | 09/04/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175334110 |
| Principal investigator 1 | Biofrontera Inc. | $18,579.44 | 08/22/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907588 |
| Principal investigator 1 | Biofrontera Inc. | $16,743.23 | 08/22/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907604 |
| Principal investigator 1 | Biofrontera Inc. | $5,000.00 | 08/22/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907607 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,164.50 | 08/20/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435197 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,308.00 | 08/18/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175333879 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,258.82 | 08/13/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435104 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $23,341.53 | 08/12/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435092 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,824.00 | 08/08/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175334070 |
| Principal investigator 1 | ABBVIE INC. | $4,000.00 | 08/05/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202501816 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,113.00 | 08/04/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,988.00 | 08/01/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333998 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,650.00 | 08/01/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435192 |
| Principal investigator 1 | ABBVIE INC. | $50,756.69 | 07/31/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202500746 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,484.00 | 07/31/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219372 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $1,300.00 | 07/16/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945823 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $8,745.75 | 07/15/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435189 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,428.00 | 07/10/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333622 |
| Principal investigator 1 | Biofrontera Inc. | $77.28 | 07/07/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY | No dispute reported | 06/30/2026 | 1208907541 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 07/07/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333546 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $100.00 | 07/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945660 |
| Principal investigator 1 | ABBVIE INC. | $11,642.00 | 07/02/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202495083 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,988.00 | 06/27/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333952 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 06/27/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175334117 |
| Principal investigator 1 | Amgen Inc. | $4,100.00 | 06/26/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER, PC | A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) | No dispute reported | 06/30/2026 | 1246649490 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $6,700.00 | 06/25/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945583 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,500.00 | 06/24/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435185 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 06/23/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,969.50 | 06/23/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 06/23/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175334007 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,500.00 | 06/23/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175334127 |
| Principal investigator 1 | Janssen Research & Development, LLC | $96.00 | 06/19/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $96.00 | 06/19/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219367 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,902.65 | 06/17/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,484.00 | 06/12/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219350 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,113.00 | 06/09/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333757 |
| Principal investigator 1 | ABBVIE INC. | $1,963.60 | 06/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202489845 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,201.00 | 05/27/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,988.00 | 05/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175334086 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 05/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184198411 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $812.00 | 05/21/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184197445 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,685.00 | 05/09/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333749 |
| Principal investigator 1 | Eli Lilly and Company | $12,580.00 | 04/28/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187890924 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,621.00 | 04/28/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175334053 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $1,200.00 | 04/24/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435082 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $9,000.00 | 04/24/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246435086 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,700.00 | 04/23/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945258 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $400.00 | 04/23/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232945262 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,581.25 | 04/11/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435173 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $23,524.00 | 04/09/2025 | Non-covered Recipient Entity The Indiana Clinical Trials Center | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | No dispute reported | 06/30/2026 | 1235993131 |
| Principal investigator 1 | ABBVIE INC. | $616.85 | 04/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202472315 |
| Principal investigator 1 | Biofrontera Inc. | $37,948.61 | 04/03/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907433 |
| Principal investigator 1 | Janssen Research & Development, LLC | $512.00 | 03/31/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333960 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,621.00 | 03/24/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333691 |
| Principal investigator 1 | Janssen Research & Development, LLC | $384.00 | 03/20/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219394 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,223.70 | 03/19/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435169 |
| Principal investigator 1 | ABBVIE INC. | $2,879.43 | 03/07/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202461259 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,322.00 | 03/06/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333796 |
| Principal investigator 1 | Biofrontera Inc. | $12.61 | 03/04/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907375 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,828.00 | 03/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175333828 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 03/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333920 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,499.00 | 03/03/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435164 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $2,600.00 | 02/25/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944906 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 02/20/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184155062 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $5,400.00 | 02/14/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163816 |
| Principal investigator 1 | Biofrontera Inc. | $17,611.53 | 02/14/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907322 |
| Principal investigator 1 | Biofrontera Inc. | $14,322.71 | 02/14/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907327 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,747.89 | 02/14/2025 | Non-covered Recipient Entity The Indiana Clinical Trials Center | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235993133 |
| Principal investigator 1 | Biofrontera Inc. | $37.20 | 02/13/2025 | Non-covered Recipient Entity INDIANA CLINICAL TRIALS CENTER | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,226.00 | 02/07/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175333895 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $6,388.20 | 02/07/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435159 |
| Principal investigator 1 | ABBVIE INC. | $2,580.45 | 02/06/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202447517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,195.00 | 01/31/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175333722 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $1,950.00 | 01/28/2025 | Non-covered Recipient Entity THE INDIANA CLINIICAL TRIALS -R-SVIP | A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | No dispute reported | 06/30/2026 | 1248163820 |
| Principal investigator 1 | Eli Lilly and Company | $231,273.00 | 01/28/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187890922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $778.00 | 01/23/2025 | Non-covered Recipient Entity The Indiana Clinic Trials Ctr | A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics | No dispute reported | 06/30/2026 | 1175219387 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $1,300.00 | 01/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944618 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $1,300.00 | 01/22/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | No dispute reported | 06/30/2026 | 1232944622 |
| Principal investigator 1 | Amgen Inc. | $57,652.32 | 01/21/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER, PC | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246649501 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,733.87 | 01/17/2025 | Non-covered Recipient Entity The Indiana Clincal Trials Center | Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | No dispute reported | 06/30/2026 | 1246435153 |
| Principal investigator 1 | Eli Lilly and Company | $6,266.23 | 01/15/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187892820 |
| Principal investigator 1 | Amgen Inc. | $110,737.49 | 01/06/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER, PC | A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies | No dispute reported | 06/30/2026 | 1246649494 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $1,649.50 | 01/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163818 |
| Principal investigator 1 | UCB SA | $48,698.10 | 01/03/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CENTER PC | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246657320 |
| Principal investigator 1 | ABBVIE INC. | $2,580.45 | 01/02/2025 | Non-covered Recipient Entity THE INDIANA CLINICAL TRIALS CTR PC | M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis | No dispute reported | 06/30/2026 | 1202434080 |